The clinical outcomes are complex and often involve multiple systems. Early identification and standardization of clinical trials are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological reactivity.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner depending on the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HL family reunification. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.